97 related articles for article (PubMed ID: 28315538)
1. Self-Administered Premedication: Improving Taxane Chemotherapy Treatment
.
Roper K; Siefert ML; Fuller F; Lucier D; Berry DL
Clin J Oncol Nurs; 2017 Apr; 21(2):234-239. PubMed ID: 28315538
[TBL] [Abstract][Full Text] [Related]
2. Optimisation of steroid prophylaxis schedules in breast cancer patients receiving docetaxel chemotherapy-a survey of health care providers and patients.
Jacobs C; Hutton B; Mazzarello S; Smith S; Joy A; Amir E; Ibrahim MF; Gregario N; Daigle K; Eggert L; Clemons M
Support Care Cancer; 2015 Nov; 23(11):3269-75. PubMed ID: 25933700
[TBL] [Abstract][Full Text] [Related]
3. Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments.
Feldweg AM; Lee CW; Matulonis UA; Castells M
Gynecol Oncol; 2005 Mar; 96(3):824-9. PubMed ID: 15721432
[TBL] [Abstract][Full Text] [Related]
4. Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial.
Takashima T; Mukai H; Hara F; Matsubara N; Saito T; Takano T; Park Y; Toyama T; Hozumi Y; Tsurutani J; Imoto S; Watanabe T; Sagara Y; Nishimura R; Shimozuma K; Ohashi Y;
Lancet Oncol; 2016 Jan; 17(1):90-8. PubMed ID: 26617202
[TBL] [Abstract][Full Text] [Related]
5. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life.
Palumbo R; Sottotetti F; Trifirò G; Piazza E; Ferzi A; Gambaro A; Spinapolice EG; Pozzi E; Tagliaferri B; Teragni C; Bernardo A
Drug Des Devel Ther; 2015; 9():2189-99. PubMed ID: 25931813
[TBL] [Abstract][Full Text] [Related]
6. Premedication Protocols to Prevent Hypersensitivity Reactions to Chemotherapy: a Literature Review.
ALMuhizi F; De Las Vecillas Sanchez L; Gilbert L; Copaescu AM; Isabwe GAC
Clin Rev Allergy Immunol; 2022 Jun; 62(3):534-547. PubMed ID: 35258842
[TBL] [Abstract][Full Text] [Related]
7. Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer.
Hudis CA; Seidman AD; Crown JP; Balmaceda C; Freilich R; Gilewski TA; Hakes TB; Currie V; Lebwohl DE; Baselga J; Raptis G; Gollub M; Robles M; Bruno R; Norton L
J Clin Oncol; 1996 Jan; 14(1):58-65. PubMed ID: 8558221
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactions.
Lin NU; Parker LM; Come SE; Burstein HJ; Haldoupis M; Ryabin N; Gelman R; Winer EP; Shulman LN
Invest New Drugs; 2007 Aug; 25(4):369-75. PubMed ID: 17345004
[TBL] [Abstract][Full Text] [Related]
9. Quality-of-life considerations with taxane-based therapy in metastatic breast cancer.
Maxwell C
Clin J Oncol Nurs; 2013 Feb; 17 Suppl():35-40. PubMed ID: 23360701
[TBL] [Abstract][Full Text] [Related]
10. Metastatic breast cancer epidemiology and management with a focus on taxanes.
Donovan D
Clin J Oncol Nurs; 2013 Feb; 17 Suppl():5-8. PubMed ID: 23360697
[TBL] [Abstract][Full Text] [Related]
11. Taxanes: impact on breast cancer therapy.
Bachegowda LS; Makower DF; Sparano JA
Anticancer Drugs; 2014 May; 25(5):512-21. PubMed ID: 24552749
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy-induced amenorrhea from adjuvant breast cancer treatment: the effect of the addition of taxanes.
Davis AL; Klitus M; Mintzer DM
Clin Breast Cancer; 2005 Dec; 6(5):421-4. PubMed ID: 16381625
[TBL] [Abstract][Full Text] [Related]
13. [The role of taxanes in breast cancer chemotherapy: what's new 15 years after?].
Herceg D; Vrbanec D
Lijec Vjesn; 2009; 131(5-6):133-41. PubMed ID: 19642533
[TBL] [Abstract][Full Text] [Related]
14. Advances in taxane therapy for metastatic breast cancer.
ONS News; 2004; 19(9 Suppl):75-6. PubMed ID: 15478598
[TBL] [Abstract][Full Text] [Related]
15. A Difference in the Incidences of Hypersensitivity Reactions to Original and Generic Taxanes.
Ratanajarusiri T; Sriuranpong V; Sitthideatphaiboon P; Poovoravan N; Vinayanuwat C; Parinyanitikul N; Angspatt P; Thawinwisan W; Tanasanvimon S
Chemotherapy; 2017; 62(2):134-139. PubMed ID: 27997900
[TBL] [Abstract][Full Text] [Related]
16. Taxanes as a first-line systemic treatment in metastatic breast cancer.
Urquhart LM
Clin J Oncol Nurs; 2013 Feb; 17 Suppl():15-21. PubMed ID: 23360699
[TBL] [Abstract][Full Text] [Related]
17. Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 women.
Pentheroudakis G; Fountzilas G; Bafaloukos D; Koutsoukou V; Pectasides D; Skarlos D; Samantas E; Kalofonos HP; Gogas H; Pavlidis N
Breast Cancer Res Treat; 2006 Jun; 97(3):237-44. PubMed ID: 16322882
[TBL] [Abstract][Full Text] [Related]
18. Hypersensitivity reactions to docetaxel: retrospective evaluation and development of a desensitization protocol.
Syrigou E; Dannos I; Kotteas E; Makrilia N; Tourkantonis I; Dilana K; Gkiozos I; Saif MW; Syrigos KN
Int Arch Allergy Immunol; 2011; 156(3):320-4. PubMed ID: 21720178
[TBL] [Abstract][Full Text] [Related]
19. Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group.
Trudeau ME; Eisenhauer EA; Higgins BP; Letendre F; Lofters WS; Norris BD; Vandenberg TA; Delorme F; Muldal AM
J Clin Oncol; 1996 Feb; 14(2):422-8. PubMed ID: 8636752
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Premedication Protocol without Ranitidine for Taxane Regimen: A Multicenter Non-Randomized Historical Controlled Study.
Chantharakhit C; Ruchakorn T; Mungkornkaew S; Amorntrakoon P; Tassanamethee S; Theeratrakul P; Sujaritvanichpong N
Asian Pac J Cancer Prev; 2022 Apr; 23(4):1331-1336. PubMed ID: 35485693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
